Aravive
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-12-10
- Employees
- 23
- Market Cap
- -
- Website
- http://www.aravive.com
- Introduction
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04983407
- Locations
- 🇺🇸
UCLA Health, Santa Monica, California, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Boca Raton Regional Hospital / Lynn Cancer Institute, Boca Raton, Florida, United States
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT04729608
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Columbus NCORP, Columbus, Ohio, United States
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04300140
- Locations
- 🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT04042623
- Locations
- 🇺🇸
Moonshine Clinical Research, Doral, Florida, United States
🇺🇦Institute of Nephrology National Academy of Medical Science Ukraine, Kyiv, Ukraine
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT03639246
- Locations
- 🇺🇸
OUHSC-Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Kaiser Permanente Vallejo, Vallejo, California, United States
🇺🇸Kaiser Permanente San Francisco, San Francisco, California, United States
A Phase 1 AVB-S6-500 Safety and Tolerability Study
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT03401528
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States